This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From The PROTECT Study Conducted At Massachusetts General Hospital Demonstrating Predictive Value Of Adverse Outcomes In Heart Failure Patients

Stocks in this article: BGMD

WALTHAM, Mass., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of the results of a clinical research study conducted at the Massachusetts General Hospital (MGH) that provide further evidence that elevated levels of galectin-3 are predictive of adverse outcomes in chronic heart failure patients and suggest that the prognostic value of this non-invasive biomarker may be enhanced when serial measurements are made over time.

In this clinical research study, which was recently published online in the European Journal of Heart Failure, first author Dr. Shweta Motiwala and colleagues of the Division of Cardiology at the Massachusetts General Hospital demonstrate that stable heart failure patients whose galectin-3 blood levels were greater than 20 ng/ml, when measured at three-month intervals, experienced 50% more cardiovascular events, including unplanned hospitalizations for heart failure, than patients whose galectin-3 levels were consistently lower than 20 ng/ml. 1 Further, these research data, which were collected from over 900 outpatient visits, also found that increases in galectin-3 levels above a threshold value of 20 ng/ml between outpatient visits, and increases in galectin-3 levels in excess of 15% at any three-month interval, were also predictive of significantly increased risk of adverse outcomes, including unplanned hospitalizations.

"We believe that the results of this research study further support a large body of evidence regarding the utility of galectin-3 as a predictor of adverse outcomes in chronic heart failure," said Dr. Paul R. Sohmer, President and CEO of BG-Medicine, Inc. "From this study, it appears that serial outpatient testing for galectin-3 may provide additional information that may facilitate decisions regarding the clinical management of stable heart failure patients."

For this clinical research study, galectin-3 levels were measured in plasma samples that had been collected as part of the PROTECT study. 2 The study enrolled 151 stable heart failure (HF) patients, with an average age of 63 years, who were followed for a median of 10 months. The HF patients who participated in the study had galectin-3 blood levels drawn at four time points during scheduled outpatient physician visits. Galectin-3 levels independently predicted cardiovascular events even after adjustment for clinically relevant variables such as treatment arm allocation, NT-proBNP level, and kidney function. No effect on galectin-3 levels was observed in association with heart failure medications that provided symptom-related or mortality-related benefits.

"Unplanned hospitalizations and unforeseen cardiovascular events are devastating to heart failure patients and their families, represent a significant challenge to health care providers and continue to be a leading cost burden on healthcare systems," stated Dr. Sohmer. "The results of this study from the Massachusetts General Hospital provide further evidence that galectin-3 testing may help to identify and facilitate triage of those heart failure patients who are at elevated risk of near-term adverse events and of deteriorating cardiac function."

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs